PRPH ProPhase Labs, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 868278 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY138.9%
TTM net income YoY45.8%
TTM EPS YoY91.5%
Revenue 3-yr CAGR-63.4%
Net income 3-yr CAGR—
Margins
Gross margin16.8%
Operating margin-404.5%
Net margin-583.9%
FCF margin—
EBITDA margin-320.1%
Returns
ROE-539.7%
ROA-45.2%
ROIC (approx.)-302.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets105.4%
Debt / equity—
Current ratio0.05x
Interest coverage-2.15x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.34M | $6.77M |
| Cost of revenue | $2.96M | $6.92M |
| Gross profit | $1.38M | -$150,000 |
| R&D expense | $107,000 | $594,000 |
| SG&A expense | $19.32M | $37.88M |
| Operating income | -$18.05M | -$38.63M |
| Interest expense | $6.93M | $3.35M |
| Pretax income | -$23.39M | -$42.33M |
| Income tax | $0 | $7.20M |
| Net income | -$14.74M | -$53.36M |
| EBITDA | -$13.21M | -$32.44M |
| EPS (basic) | -1.74 | -26.68 |
| EPS (diluted) | -1.74 | -26.68 |
| Weighted avg. shares (diluted) | 8.49M | 2.00M |
| Banking | ||
| Provision for credit losses | — | $0 |
| Balance sheet | ||
| Cash & equivalents | $90,000 | $678,000 |
| Short-term investments | $0 | $3.13M |
| Receivables | $1.54M | $20.06M |
| Inventory | $70,000 | $1.14M |
| Current assets | $3.15M | $30.64M |
| PP&E, net | $2.03M | $7.50M |
| Goodwill | $3.97M | $5.23M |
| Intangibles | $7.17M | $9.75M |
| Total assets | $59.87M | $63.20M |
| Current liabilities | $53.08M | $32.13M |
| Short-term debt | — | $3.21M |
| Total liabilities | $56.36M | $55.85M |
| Shareholders' equity | $3.51M | $7.35M |
| Shares outstanding | 8.97M | 2.99M |
| Cash flow statement | ||
| Operating cash flow | -$8.34M | -$17.54M |
| Capital expenditure | $0 | $906,000 |
| Free cash flow | -$8.34M | -$18.44M |
| Investing cash flow | $920,000 | $2.42M |
| Financing cash flow | $6.84M | $14.19M |
| Depreciation & amortization | $4.83M | $6.19M |
| Stock-based compensation | $1.89M | $3.64M |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.